Selskabets formål er at drive handel og fabrikation samt dertil knyttet virksomhed
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1 mia. | 46.1 mio. | 642.6 mio. | 291.7 mio. | 48 | |
CVR: 13902992
Secondary names: DERMALOG ApS, PHARMACODANE ApS
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 27478700
CVR 45320618
CVR 45224260
CVR 51619811
CVR 37720089
STADA NORDIC ApS demonstrates a strong financial health with a significant upward trajectory in revenue and profit over the past few years. In 2024, the company reported revenue of 1.03 billion DKK and a profit of 46.1 million DKK, marking a substantial increase from 808.7 million DKK in revenue and 66.4 million DKK in profit in 2023. The equity position has also improved, rising to 291.7 million DKK, which indicates a solid foundation for future growth. However, profit margins have slightly decreased, suggesting potential concerns regarding cost management. Overall, STADA NORDIC ApS is well-positioned within the pharmaceutical wholesale industry, reflecting robust growth and stability.
AI-generated summary
companydata.dk